A THC:CBD ratio compares the relative amount of THC and CBD in a product. A 1:1 label means the two amounts are broadly equal; a THC-dominant label has more THC relative to CBD; a CBD-dominant label has more CBD relative to THC.
That is useful composition information. The ratio still leaves out the amount used, the formulation, what reaches the bloodstream, possible side effects, clinical suitability and fitness to drive.
The information a ratio leaves out
The same stated ratio can appear in products with different total cannabinoid amounts and different formulations. It also leaves out other constituents and the context in which a medicine is prescribed. Reading a ratio without those details is like knowing a proportion without knowing the size of what is being compared.
For the separate evidence and regulatory context around each compound, read THC, CBD and the cannabinoid reference.
Findings from a controlled oral study
A randomised, double-blind crossover clinical-pharmacology study tested 18 healthy adults on three occasions. It compared two oral cannabis extracts with the same amount of THC: one contained THC alone and the other contained THC with a much larger amount of CBD. The CBD-containing extract produced higher measured THC and metabolite exposure and more reported anxiety, sedation, memory difficulty and cognitive or psychomotor impairment in that experiment.
That finding challenges the slogan that CBD always offsets THC. The study used particular oral preparations, one THC amount, healthy adults and a controlled setting. Its result does not extend to UK prescribed patients, other formulations, all ratios or treatment benefit.
Ratios, safety and driving
A ratio cannot choose a product, set a dose or replace clinical monitoring. It cannot predict whether a person will have an adverse effect or whether a medicine will interact with other medicines. It also cannot provide driving clearance. UK drug-driving law includes rules about impairment and prescribed medicines; a number on a label is not an individual legal assessment.
A CBD-dominant label still needs the same care. CBD has its own formulation-specific evidence and medicine-interaction considerations. The CBD versus THC explainer covers the different evidence behind each name.
Keeping a ratio in context
A ratio explains what the label is comparing. The remaining questions concern the exact product, instructions, other medicines, intended monitoring and individual circumstances. The MCPH glossary explains the terminology; patient-specific questions belong with the prescriber or pharmacist.
Sources
- Oral THC when coadministered with CBD (PMID 36780161; DOI); randomised double-blind crossover pharmacokinetic and pharmacodynamic study in 18 healthy adults using specified oral extracts; not a universal ratio rule.
- Medical cannabis (NHS); general THC/CBD patient context, not ratio-selection guidance.
- Drugs and driving: the law (GOV.UK); a label cannot supply personal driving clearance.
- CBD evidence page and THC evidence page (MCPH); source-specific evidence summaries, not ratio recommendations.
